Efficacy of tezepelumab in patients with severe allergic asthma in clinical practice
Main Article Content
Keywords
Tezepelumab., Allergic asthma. , Real-life. , Efficacy.
Abstract
Introduction: Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). In clinical trials, tezepelumab has been shown to reduce the annualized asthma exacerbation rate in patients with both high and low levels of T2 inflammation biomarkers.
Methods: This is a prospective, multicenter study of RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) conducted under routine clinical practice conditions. We analyzed exacerbations, changes in lung function (pre-bronchodilator FEV1), asthma control (ACT), and quality of life (mini AQLQ). In addition, T2 biomarkers, including blood eosinophils and exhaled nitric oxide (FeNO), were analyzed.
Results: We present a series of 38 patients with severe allergic asthma who received treatment with tezepelumab. More than half of these patients had previously shown inadequate responses to other biologic therapies. Following treatment, the annualized rate of exacerbations decreased markedly from a baseline mean of 2.2 to 0.28, representing an 86.8% reduction. The Asthma Control Test (ACT) score improved by an average of 5.2 points, while the mini Asthma Quality of Life Questionnaire (miniAQLQ) score increased by 1 point. Pulmonary function also improved significantly, with a mean increase of 170 mL in FEV1. Furthermore, type 2 inflammatory biomarkers, including blood eosinophil counts and fractional exhaled nitric oxide (FeNO), showed a significant reduction.
Conclusions: Tezepelumab is an effective treatment for severe allergic asthma, improving exacerbations, disease control, quality of life, and lung function.
References
2. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–9. https://doi.org/10.1056/NEJMoa2034975
3. Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, et al. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. Lancet Respir Med. 2023;11(5):425–38. https://doi.org/10.1016/S2213-2600(22)00492-1
4. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-36. https://doi.org/10.2147/JAA.S342391
5. Corren J, Ambrose CS, Sałapa K, Roseti SL, Griffiths JM, Parnes JR, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy. J Allergy Clin Immunol Pract. 2021;9(12):4334–42. https://doi.org/10.1016/j.jaip.2021.07.045
6. Corren J, Ambrose CS, Griffiths JM, Hellqvist Å, Lindsley AW, Llanos JP, et al. Efficacy of tezepelumab in patients with evidence of severe allergic asthma: results from the phase 3 NAVIGATOR study. Clin Exp Allergy. 2023;53(4):417–28. https://doi.org/10.1111/cea.14256
7. Gates J, Haris F, Cefaloni F, Khooshemehri P, Green L, Fernandes M, et al. Clinical and Biological Remission With Tezepelumab: The Real-World Response in Severe Uncontrolled Asthma. Allergy. 2025 May 14. https://doi.org/10.1111/all.16590
8. Lugogo NL, Akuthota P, Sumino K, Mathur SK, Burnette AF, Lindsley AW, et al. Effectiveness and Safety of tezepelumab in a diverse population of US patients with severe asthma: initial results of the PASSAGE study. Adv Ther. 2025 Jul;42(7):3334–53. https://doi.org/10.1007/s12325-025-03231-6
9. Miralles-López JC, Andújar-Espinosa R, Bravo-Gutierrez FJ, Cabrejos-Perotti S, Ramírez-Hernández M, Díaz-Chantar C, et al. Tezepelumab in patients with severe asthma: response at 3 months. J Investig Allergol Clin Immunol. 2025 Apr 22;35(2):132–134. https://doi.org/10.18176/jiaci.1041
10. Miralles-López JC, Bravo-Gutierrez FJ, Andújar-Espinosa R, Castilla-Martínez M, Díaz-Chantar C, Ramírez-Hernández M, et al. Real-life effectiveness of tezepelumab in severe asthma. Allergol Immunopathol (Madr). 2025 Mar;53(2):163–73. https://doi.org/10.15586/aei.v53i2.1326
11. Biener L, Mümmler C, Hinze CA, Suhling H, Korn S, Fisser C, et al. Real-world data on tezepelumab in patients with severe asthma in Germany. J Allergy Clin Immunol Pract. 2024 Sep;12(9):2399–407. https://doi.org/10.1016/j.jaip.2024.05.052
12. Marra AM, Biagioni B, Bini F, Cecchi L. Is tezepelumab the treatment option of choice in severe allergic asthma? Eur Ann Allergy Clin Immunol. 2025 Apr 8. https://doi.org/10.23822/EurAnnACI.1764-1489.399
13. Caminati M, Buhl R, Corren J, Hanania NA, Kim H, Korn S, et al. Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024;79:1134-45. https://doi.org/10.1111/all.15986
